Go Deep
ADR Biomedical Holdings Inc.
ADR Biomedical Holdings Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | -64,546 | -12.1 | -94.52 | 0.00 | 459.47 |
| Oct 2026 | -64,413 | -11.8 | -92.90 | 0.00 | 450.74 |
| Oct 2026 | -66,993 | -12.0 | -97.64 | 0.00 | 472.60 |
ADR Biomedical Holdings Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 57,728,000.0 | 17,292,000.0 | 15,416,000.0 | 12,139,000.0 |
| Net Profit | -93,674,000.0 | -79,916,000.0 | -185,865,000.0 | -200,902,000.0 |
| EPS | -10.5 | — | — | — |
ADR Biomedical Holdings Inc. Revenue & Profit: Last 5 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Revenue | 50,988,000.0 | 122,204,000.0 | 1,560,388,000.0 | 2,144,712,000.0 | — |
| Net Profit | -396,904,000.0 | -2,140,086,000.0 | 138,155,000.0 | -1,059,941,000.0 | — |
| EPS | -44.5 | -239.7 | 15.5 | -118.7 | — |
ADR Biomedical Holdings Inc. Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Total Assets | 368,058,000.0 | 3,537,592,000.0 | 5,816,334,000.0 | 14,091,635,000.0 | — |
| Total Liabilities | 346,032,000.0 | 2,907,056,000.0 | 3,020,748,000.0 | 11,434,954,000.0 | — |
| Total Equity | 22,026,000.0 | 630,536,000.0 | 2,790,795,000.0 | 2,652,674,000.0 | — |
Owes vs Owns
ADR Biomedical Holdings Inc. owed ¥1.20 for every ¥1 it owned in Jun 2026, up from ¥0.81 in Mar 2023.
| Period | Jun 2026 | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|---|
| Owes vs Owns | 1.20× | 0.94× | 0.82× | 0.52× | 0.81× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
ADR Biomedical Holdings Inc. Assets & Liabilities Breakdown (JPY millions)
What it owns — Mar 2026
Cash & short-term investments 34.2%Receivables 2.2%Inventory 18.0%Long-term investments 2.8%Other assets 42.7%
How it's funded — Mar 2026
Other liabilities 93.6%Shareholders' equity 6.0%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 125.9 | 256.0 | 1,038.2 | 1,123.0 |
| Receivables | 8.2 | 2.3 | 58.3 | 113.1 |
| Inventory | 66.4 | 52.7 | 103.5 | 116.2 |
| Fixed assets (tangible) | 0.0 | 2,960.3 | 4,217.5 | 11,727.2 |
| Intangible assets | 0.0 | 2.0 | 21.3 | 688.8 |
| Long-term investments | 10.2 | 0.2 | 0.0 | 0.0 |
| Other assets | 157.3 | 264.1 | 377.4 | 323.2 |
| Liabilities & equity | ||||
| Short-term debt | 0.0 | 354.3 | 124.7 | 901.2 |
| Long-term debt | 0.0 | 2,293.9 | 2,347.1 | 7,605.9 |
| Payables | 1.6 | 0.3 | 0.0 | 0.0 |
| Other liabilities | 344.4 | 258.5 | 549.0 | 2,927.9 |
| Shareholders' equity | 22.0 | 630.5 | 2,795.6 | 2,656.7 |
| Net tangible assets | 22.0 | 628.5 | 2,769.5 | 1,963.8 |
ADR Biomedical Holdings Inc. Cash Flow
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Operating Activities | -784,773,000.0 | -987,038,000.0 | -1,152,230,000.0 | -39,518,000.0 | — |
| Investing Activities | 2,979,364,000.0 | 22,901,000.0 | 8,689,978,000.0 | -283,065,000.0 | — |
| Financing Activities | -2,321,675,000.0 | 171,650,000.0 | -7,172,572,000.0 | 294,227,000.0 | — |